JP6306507B2 - 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 - Google Patents

制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 Download PDF

Info

Publication number
JP6306507B2
JP6306507B2 JP2014526308A JP2014526308A JP6306507B2 JP 6306507 B2 JP6306507 B2 JP 6306507B2 JP 2014526308 A JP2014526308 A JP 2014526308A JP 2014526308 A JP2014526308 A JP 2014526308A JP 6306507 B2 JP6306507 B2 JP 6306507B2
Authority
JP
Japan
Prior art keywords
clostridium
cells
mice
dna
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014526308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500792A5 (OSRAM
JP2015500792A (ja
Inventor
賢也 本田
賢也 本田
幸二 新
幸二 新
大 田ノ上
大 田ノ上
正平 服部
正平 服部
英利 森田
英利 森田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
School Corp Azabu Veterinary Medicine Educational Inst
Original Assignee
University of Tokyo NUC
School Corp Azabu Veterinary Medicine Educational Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48535050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6306507(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Tokyo NUC, School Corp Azabu Veterinary Medicine Educational Inst filed Critical University of Tokyo NUC
Publication of JP2015500792A publication Critical patent/JP2015500792A/ja
Publication of JP2015500792A5 publication Critical patent/JP2015500792A5/ja
Application granted granted Critical
Publication of JP6306507B2 publication Critical patent/JP6306507B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
JP2014526308A 2011-12-01 2012-11-29 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 Active JP6306507B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161565976P 2011-12-01 2011-12-01
US61/565,976 2011-12-01
US201261607360P 2012-03-06 2012-03-06
US61/607,360 2012-03-06
PCT/JP2012/007687 WO2013080561A1 (en) 2011-12-01 2012-11-29 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017213526A Division JP6492151B2 (ja) 2011-12-01 2017-11-06 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌

Publications (3)

Publication Number Publication Date
JP2015500792A JP2015500792A (ja) 2015-01-08
JP2015500792A5 JP2015500792A5 (OSRAM) 2016-06-16
JP6306507B2 true JP6306507B2 (ja) 2018-04-18

Family

ID=48535050

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2014526308A Active JP6306507B2 (ja) 2011-12-01 2012-11-29 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
JP2017213526A Active JP6492151B2 (ja) 2011-12-01 2017-11-06 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
JP2019038453A Active JP7097838B2 (ja) 2011-12-01 2019-03-04 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
JP2021005834A Active JP7165218B2 (ja) 2011-12-01 2021-01-18 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
JP2022168855A Active JP7503273B2 (ja) 2011-12-01 2022-10-21 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
JP2024087782A Pending JP2024129016A (ja) 2011-12-01 2024-05-30 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017213526A Active JP6492151B2 (ja) 2011-12-01 2017-11-06 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
JP2019038453A Active JP7097838B2 (ja) 2011-12-01 2019-03-04 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
JP2021005834A Active JP7165218B2 (ja) 2011-12-01 2021-01-18 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
JP2022168855A Active JP7503273B2 (ja) 2011-12-01 2022-10-21 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
JP2024087782A Pending JP2024129016A (ja) 2011-12-01 2024-05-30 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌

Country Status (10)

Country Link
US (11) US10238694B2 (OSRAM)
EP (4) EP4477750A3 (OSRAM)
JP (6) JP6306507B2 (OSRAM)
CN (3) CN104160014A (OSRAM)
CA (1) CA2892588A1 (OSRAM)
DK (2) DK3569690T3 (OSRAM)
ES (2) ES2993669T3 (OSRAM)
FI (2) FI3978598T3 (OSRAM)
HK (1) HK1204008A1 (OSRAM)
WO (1) WO2013080561A1 (OSRAM)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
KR20130098320A (ko) 2010-08-04 2013-09-04 토마스 줄리어스 보로디 분변 세균총 이식을 위한 조성물, 그의 제조 방법과 사용 방법, 및 그를 전달하기 위한 장치
HUE038600T2 (hu) 2010-10-07 2018-10-29 California Inst Of Techn Probiotikus terápiák autizmushoz
CN103561752B (zh) 2011-03-09 2016-04-20 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN104160014A (zh) * 2011-12-01 2014-11-19 国立大学法人东京大学 诱导调节性t细胞的增殖或积累的人源细菌
CN104780932A (zh) 2012-02-29 2015-07-15 伊西康内外科公司 微生物区系的组合物及与其相关的方法
CA2868362C (en) 2012-03-29 2018-07-31 Jerome Schentag Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
CN114949001A (zh) 2012-08-29 2022-08-30 加州理工学院 孤独症谱系障碍的诊断和治疗
NZ709392A (en) 2012-11-23 2016-10-28 Seres Therapeutics Inc Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
JP2016509003A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
BR112015023124A2 (pt) 2013-03-14 2017-07-18 Therabiome Llc liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal
AU2014232370B2 (en) 2013-03-15 2018-11-01 Société des Produits Nestlé S.A. Network-based microbial compositions and methods
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
DK3074027T3 (da) 2013-11-25 2025-03-17 Nestle Sa Synergistiske bakteriesammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
WO2015095241A2 (en) 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6617935B2 (ja) 2014-04-10 2019-12-11 国立研究開発法人理化学研究所 Ｔｈ１７細胞の誘導のための組成物及び方法
US20150322176A1 (en) * 2014-04-16 2015-11-12 University Of Guelph Novel polysaccharide immunogens from clostridium bolteae isolated from autistic subjects and methods and uses thereof
US20170087196A1 (en) * 2014-05-19 2017-03-30 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
CA2966360C (en) 2014-10-30 2023-09-05 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
US10124025B2 (en) 2014-10-30 2018-11-13 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
ES3010296T3 (en) * 2014-11-25 2025-04-02 Memorial Sloan Kettering Cancer Center Intestinal microbiota and gvhd
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
KR102523805B1 (ko) 2014-12-23 2023-04-20 4디 파마 리서치 리미티드 면역 조정
KR20170091157A (ko) 2014-12-23 2017-08-08 4디 파마 리서치 리미티드 피린 폴리펩티드 및 면역 조정
WO2016110768A1 (en) * 2015-01-07 2016-07-14 Ecole Polytechnique Federale De Lausanne (Epfl) Gastro-intestinal biomarkers for diagnosis and therapies of proteinopathies
KR102561989B1 (ko) 2015-05-14 2023-07-31 핀치 테라퓨틱스 홀딩스 엘엘씨 대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치
KR102358879B1 (ko) 2015-05-22 2022-02-08 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법
RS59038B1 (sr) 2015-06-15 2019-08-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP6426264B2 (ja) 2015-06-15 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
PL3240554T3 (pl) * 2015-06-15 2020-02-28 4D Pharma Research Limited Blautia stercosis i wexlerae do stosowania w leczeniu chorób zapalnych i autoimmunologicznych
JP2018519295A (ja) * 2015-06-22 2018-07-19 プレジデント アンド フェローズ オブ ハーバード カレッジ 粘膜固有層調節性ｔ細胞の誘導
WO2017120495A1 (en) 2016-01-07 2017-07-13 Ascus Biosciences, Inc. Methods for improving milk production by administration of microbial consortia
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
JP6839666B2 (ja) 2015-06-25 2021-03-10 ネイティブ マイクロビアルズ， インコーポレイテッド 複雑な異種群集由来微生物株の解析、機能的な関係及びそれらの相互作用の予測及び同定、ならびにそれに基づく微生物アンサンブルの選択及び合成のための方法、装置、及びシステム
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
CN108350503B (zh) * 2015-09-09 2022-09-16 普梭梅根公司 用于甲状腺健康问题相关病症的源自微生物群系的诊断及治疗方法和系统
EP3370748B1 (en) * 2015-11-03 2022-06-08 The Brigham and Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of food allergy
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CA3005781C (en) 2015-11-20 2019-01-22 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520638D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MX2018006283A (es) * 2015-11-24 2019-09-06 Seres Therapeutics Inc Composiciones bacterianas diseñadas.
JP6675752B2 (ja) * 2016-02-23 2020-04-01 国立大学法人佐賀大学 腸内Ｂｌａｕｔｉａ ｃｏｃｃｏｉｄｅｓ増殖刺激剤
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
HK1246670B (en) 2016-03-04 2020-05-15 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
EP3429604A1 (en) 2016-03-14 2019-01-23 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
WO2017160944A2 (en) 2016-03-15 2017-09-21 The Regents Of The University Of Michigan Compositions and methods for treating and preventing graft versus host disease
WO2017212064A1 (en) 2016-06-10 2017-12-14 N.V. Nutricia Risk of allergy and nutrition to reduce that risk
KR102554351B1 (ko) * 2016-06-14 2023-07-13 베단타 바이오사이언시즈, 인크. 클로스트리디움 디피실레 감염의 치료
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
WO2017218956A1 (en) 2016-06-17 2017-12-21 New York University Methods and compositions for treating dysbiosis and gatrointestinal and inflammatory disorders
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US20180185421A1 (en) * 2016-08-29 2018-07-05 Tokyo Metropolitan Government Composition comprising fecal microbiota
BR112019006041A2 (pt) * 2016-09-27 2019-09-03 Board Of Regents, The University Of Texas System métodos para aprimorar a terapia de bloqueio do ponto de verificação imunológico por modulação do microbioma
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
EP4660295A2 (en) 2016-10-28 2025-12-10 Vedanta Biosciences, Inc. Methods and compositions for preserving bacteria
EP3546566A4 (en) * 2016-11-01 2020-05-27 Keio University TH1 CELL INDUCING BACTERIA
US11571446B2 (en) * 2016-11-18 2023-02-07 Sanford Bumham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN110062806B (zh) * 2016-12-13 2022-08-05 深圳华大生命科学研究院 粪厌氧棒杆菌(Anaerostipes caccae)及其应用
AU2017381697B2 (en) 2016-12-23 2020-12-24 Keio University Compositions and methods for the induction of CD8+ T-cells
US12018313B2 (en) 2016-12-28 2024-06-25 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities with tracer analytics, determination of functional relationships and interactions thereof, and synthesis of microbial ensembles
JP2020504620A (ja) 2016-12-28 2020-02-13 アスカス バイオサイエンシーズ， インコーポレイテッド 複雑な不均一コミュニティの完全微生物株の解析、その機能的関連性及び相互作用の決定、ならびにそれに基づく生物反応性の改変剤の同定及び合成、のための方法、装置、及びシステム
JP2020506968A (ja) * 2017-02-07 2020-03-05 カリフォルニア インスティチュート オブ テクノロジー ハンチントン病およびレット症候群における腸内微生物叢の調節
US10596206B1 (en) 2017-03-14 2020-03-24 Cornell University Probiotic compositions and methods of use
EP3606325B1 (en) 2017-04-03 2024-09-04 Gusto Global, LLC Rational design of microbial-based biotherapeutics
EP3606541A1 (en) 2017-04-05 2020-02-12 Crestovo Holdings LLC Compositions and methods for treating parkinson's disease (pd) and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CA3057692A1 (en) 2017-04-28 2018-11-01 Ascus Biosciences, Inc. Methods for supporting grain intensive and/or energy intensive diets in ruminants by administration of a synthetic bioensemble of microbes or purified strains thereof
WO2018213262A1 (en) * 2017-05-19 2018-11-22 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing listeria monocytogenes infection or colonization
EP3630136B1 (en) 2017-05-22 2021-04-21 4D Pharma Research Limited Compositions comprising bacterial strains
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3630190B1 (en) 2017-05-26 2024-02-21 Finch Therapeutics Holdings LLC Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
WO2018229188A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
HUE052258T2 (hu) 2017-06-14 2021-04-28 4D Pharma Res Ltd Megasphaera nemzetségbe tartozó baktériumtörzset tartalmazó készítmény, és alkalmazása
EP3600363B1 (en) 2017-06-14 2020-12-02 4D Pharma Research Limited Compositions comprising bacterial strains
GB201709763D0 (en) * 2017-06-19 2017-08-02 Probi Ab Biological materials and methods
WO2019028402A1 (en) * 2017-08-04 2019-02-07 Second Genome, Inc. ROSEBURIA HOMINIS, EUBACTERIUM ELIGENS AND COMBINATIONS THEREOF AS BIOTHERAPEUTIC AGENTS
CN111328331A (zh) * 2017-08-07 2020-06-23 芬奇治疗公司 用于将肠道中的抗生素抗性细菌去定植的组合物和方法
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP3703720A1 (en) 2017-10-30 2020-09-09 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
EP3476396A1 (en) * 2017-10-31 2019-05-01 Institut Gustave Roussy Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same
AU2018365071B2 (en) * 2017-11-09 2025-09-11 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy
US10507221B2 (en) 2017-11-09 2019-12-17 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy
EP3723776A4 (en) * 2017-12-11 2022-07-27 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
US20200368293A1 (en) * 2018-01-18 2020-11-26 Vedanta Biosciences, Inc. Compositions and methods for the treatment of cancer
CN111886333A (zh) 2018-02-09 2020-11-03 学校法人庆应义塾 诱导cd8+t细胞的组合物和方法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3594321A1 (en) * 2018-07-10 2020-01-15 Université catholique de Louvain Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof
PL3820573T3 (pl) 2018-07-10 2024-02-19 Novartis Ag Pochodne 3-(5-hydroksy-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu i ich zastosowanie w leczeniu chorób zależnych od palca cynkowego z rodziny ikaros 2 (ikzf2)
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
WO2020018949A2 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
DE102018213030A1 (de) * 2018-08-03 2020-02-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien
IL280779B2 (en) * 2018-08-17 2025-05-01 Vedanta Biosciences Inc Compositions for use in the treatment or prevention of Clostridium difficile infection
KR20210065969A (ko) 2018-09-27 2021-06-04 핀치 테라퓨틱스 홀딩스 엘엘씨 간질 및 관련 장애를 치료하기 위한 조성물 및 방법
WO2020071463A1 (ja) * 2018-10-04 2020-04-09 国立研究開発法人理化学研究所 ＩＬＣ２を標的としたＩｇＡ産生誘導方法
AU2019374773B2 (en) * 2018-11-05 2025-10-16 Clostrabio Methods and compositions for treating infectious, autoimmune, and allergic disease
WO2020234746A1 (en) 2019-05-18 2020-11-26 Janssen Biotech, Inc. Materials and methods for microbiome modulation
WO2021011887A1 (en) * 2019-07-17 2021-01-21 University Of Utah Research Foundation Clostridia consortia compositions and methods of treating obesity, metabolic syndrome and irritable bowel disease
PE20221399A1 (es) 2019-07-19 2022-09-15 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales
JP2022544369A (ja) * 2019-08-14 2022-10-18 ヴァーヘニンゲン・ウニヴェルシテイト ミオ－イノシトール－プロピオネート経路を含む細菌
EP4013851A1 (en) 2019-08-16 2022-06-22 Janssen Biotech, Inc. Optimized culture media for clostridia bacteria
US20250270498A1 (en) * 2019-08-16 2025-08-28 Janssen Biotech, Inc. Optimized culture media for clostridia bacteria
US20220282206A1 (en) 2019-08-16 2022-09-08 Janssen Biotech, Inc. Optimized culture media for clostridia bacteria
JP2021045097A (ja) * 2019-09-20 2021-03-25 腸内フローラ移植臨床研究株式会社 腸内フローラの健康状態の診断方法及びその利用
WO2021102313A1 (en) * 2019-11-22 2021-05-27 Assembly Biosciences, Inc. Compositions comprising bacterial species and methods related thereto
US20230131960A1 (en) * 2020-03-25 2023-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to treat and prevent diseases caused by enterobacteriae
EP3895710A1 (en) 2020-04-15 2021-10-20 DSM IP Assets B.V. Food and/or feed compositions to manage immune homeostasis
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
BR112022023687A2 (pt) * 2020-05-21 2022-12-20 Superbrewed Food Inc Método de tratar ou prevenir uma infecção
US12011467B2 (en) 2021-05-18 2024-06-18 J. Craig Venter Institute, Inc. Bacterial formulation
CN116195742B (zh) * 2021-11-30 2024-07-09 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在保护软骨中的应用
JPWO2023100977A1 (OSRAM) * 2021-12-02 2023-06-08
CN119970806A (zh) * 2025-02-25 2025-05-13 浙江大学 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0030615B1 (en) 1979-11-16 1984-08-29 STEROSYNT Ltd. 6-alpha-9-alpha-difluoro-16-beta-methyl-prednisolone-17,21 diesters and pharmaceutical compositions containing them
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US5700787A (en) 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
ATE407700T1 (de) 1996-03-20 2008-09-15 Univ New South Wales Veränderung der mikrobenflora im verdauungstrakt
US6551632B2 (en) 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
JP2001112485A (ja) 1999-10-19 2001-04-24 Yakult Honsha Co Ltd 腸内細菌用プライマー及び該プライマーを用いた検出方法
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
US7094555B2 (en) 2001-04-05 2006-08-22 Benaroya Research Institute At Virginia Mason Methods of MHC class II epitope mapping, detection of autoimmune T cells and antigens, and autoimmune treatment
PE20030283A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
GB0220809D0 (en) * 2002-09-06 2002-10-16 Univ College Of London Immune modulator
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
CA2520865A1 (en) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2004104175A2 (en) 2003-05-14 2004-12-02 University Of Georgia Research Foundation, Inc. Probiotic bacteria and methods
JP2005124495A (ja) 2003-10-24 2005-05-19 Yakult Honsha Co Ltd ヒト腸内細菌検出用プライマー
US20070178072A1 (en) 2004-03-31 2007-08-02 Kirin Beer Kabushiki Kaisha Method for inducing differentiation of regulatory t cells usinggip-anchored protein agonist and pharmaceutical composition therefor ( as amended
US8092793B2 (en) 2004-12-15 2012-01-10 Qingdao East Sea Pharmaceuticals, Ltd. Treating inflammatory bowel disease with live bacteria
AU2006219475B8 (en) 2005-03-03 2013-02-07 Meiji Co., Ltd. Immune function modulating agents
CU23581A1 (es) 2005-10-28 2010-10-30 Ct Ingenieria Genetica Biotech Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
EP1964570B1 (de) 2007-03-02 2012-11-21 Protectimmun GmbH Pharmazeutische Zusammensetzung zum Schutz vor Allergien und entzündlichen Erkrankungen
EP1974743A1 (en) 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
CN101310730A (zh) 2007-05-27 2008-11-26 青岛东海药业有限公司 酪酸梭菌在制备防治类风湿性关节炎、强直性脊柱炎微生物制剂中的应用
WO2010093861A2 (en) 2009-02-13 2010-08-19 The Regents Of The University Of Calfornia System, method and device for tissue-based diagnosis
JP2009084215A (ja) 2007-09-28 2009-04-23 Nippon Paper Chemicals Co Ltd 炎症性腸疾患予防・治療剤
WO2009050486A2 (en) 2007-10-19 2009-04-23 The University Of Surrey Peptide manipulators of regulatory t cell activity
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
CN101496819A (zh) 2008-01-31 2009-08-05 青岛东海药业有限公司 真杆菌、梭菌制剂及其应用
KR100913405B1 (ko) 2008-03-25 2009-08-21 광주과학기술원 Ｔｈ２－매개 면역 질환의 예방 또는 치료용 조성물
US8586029B2 (en) 2008-06-04 2013-11-19 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
JP2010129134A (ja) 2008-11-28 2010-06-10 Pulstec Industrial Co Ltd ホログラム記録装置及びホログラム再生装置
GB0903016D0 (en) 2009-02-23 2009-04-08 Univ Gent Method for alleviating intestinal problems and novel bacterial strains therefor
US20100275282A1 (en) 2009-04-23 2010-10-28 Round June L Methods and systems for identifying immunomodulatory substances
US20100311686A1 (en) 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
WO2011022542A2 (en) 2009-08-19 2011-02-24 Puretech Ventures, Llc Administration of factors normally present in a microbial niche to improve health
WO2011022660A1 (en) 2009-08-21 2011-02-24 Puretech Ventures, Llc Methods of diagnosing and treating microbiome-associated disease using interaction network parameters
WO2011027956A2 (ko) 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
US20120276149A1 (en) * 2009-10-15 2012-11-01 Dan Littman Methods for modulating bacterial infection
ES2610829T3 (es) 2009-11-11 2017-05-03 Alimentary Health Limited Cepa de Bifidobacterium
EP2556835B1 (en) * 2010-02-10 2015-08-05 Japan Eco-Science Co. Ltd. Mixture, dissolving solution and pharmaceutical agent each comprising thermophilic microorganism
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
US20120020941A1 (en) 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
EP2598155A2 (en) 2010-07-26 2013-06-05 Suomen Punainen Risti Veripalvelu Use of blood group status iii
ES2388662B1 (es) 2010-11-10 2014-04-11 Consejo Superior De Investigaciones Científicas (Csic) Nuevas cepas de duganella aisladas de la rizosfera de olivo silvestre y cultivado y su uso en la producción de violaceína.
US20120279149A1 (en) * 2011-05-04 2012-11-08 Sebastian George Quinn System and device for utilization of energy in buildings
US20140171339A1 (en) * 2011-06-06 2014-06-19 The University Of North Carolina At Chapel Hill Methods and kits for detecting adenomas, colorectal cancer, and uses thereof
CA2848757C (en) 2011-09-14 2021-11-09 University Of Guelph Methods to culture human gastrointestinal microorganisms
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN104160014A (zh) * 2011-12-01 2014-11-19 国立大学法人东京大学 诱导调节性t细胞的增殖或积累的人源细菌
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2014078911A1 (en) 2012-11-26 2014-05-30 Borody Thomas J Compositions for the restoration of a fecal microbiota and methods for making and using them
JP2016509003A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
WO2014153194A2 (en) 2013-03-14 2014-09-25 Seres Health, Inc. Methods for pathogen detection and enrichment from materials and compositions
BR112015023124A2 (pt) 2013-03-14 2017-07-18 Therabiome Llc liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal
AU2014232370B2 (en) 2013-03-15 2018-11-01 Société des Produits Nestlé S.A. Network-based microbial compositions and methods
EP3019181A4 (en) * 2013-07-09 2016-09-21 Puretech Ventures Llc COMPOSITIONS WITH COMBINATIONS OF BIOACTIVE MOLECULARS DERIVED FROM MICROBOTS FOR TREATING DISEASES
JP6617935B2 (ja) 2014-04-10 2019-12-11 国立研究開発法人理化学研究所 Ｔｈ１７細胞の誘導のための組成物及び方法
WO2015198105A1 (en) 2014-06-27 2015-12-30 Telefonaktiebolaget L M Ericsson (Publ) System and method for supporting time-sensitive services in a communication network
MX381919B (es) 2014-06-30 2025-03-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
CA2987013C (en) 2015-05-30 2022-05-31 Japan Eco-Science Co., Ltd. Probiotic or prebiotic, method for producing same, microbial preparation, health food, and medicine
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
US9642281B1 (en) * 2015-12-28 2017-05-02 Martas Precision Slide Co., Ltd. Buckle set for sliding rail of industrial rackmount chassis
EP3429604A1 (en) * 2016-03-14 2019-01-23 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
US20170290889A1 (en) 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
JP6792103B2 (ja) 2016-06-01 2020-11-25 株式会社テックコーポレーション 微細気泡水供給システム
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
EP3546566A4 (en) 2016-11-01 2020-05-27 Keio University TH1 CELL INDUCING BACTERIA
AU2017381697B2 (en) * 2016-12-23 2020-12-24 Keio University Compositions and methods for the induction of CD8+ T-cells
CN111328331A (zh) 2017-08-07 2020-06-23 芬奇治疗公司 用于将肠道中的抗生素抗性细菌去定植的组合物和方法
JP2019046634A (ja) * 2017-08-31 2019-03-22 パナソニックＩｐマネジメント株式会社 照明システム及びコントローラ
US10507221B2 (en) * 2017-11-09 2019-12-17 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy

Also Published As

Publication number Publication date
EP3569690B1 (en) 2024-08-28
JP2018039833A (ja) 2018-03-15
US20190314426A1 (en) 2019-10-17
FI3569690T3 (fi) 2024-11-18
US20160193257A1 (en) 2016-07-07
DK3978598T3 (da) 2024-11-11
JP2021078504A (ja) 2021-05-27
JP2024129016A (ja) 2024-09-26
US20190046591A1 (en) 2019-02-14
WO2013080561A1 (en) 2013-06-06
CN108676774A (zh) 2018-10-19
EP3569690A1 (en) 2019-11-20
EP2785828B1 (en) 2020-04-08
US20190030092A1 (en) 2019-01-31
US20240000858A1 (en) 2024-01-04
CN108676774B (zh) 2023-05-09
US9649345B2 (en) 2017-05-16
JP7097838B2 (ja) 2022-07-08
CA2892588A1 (en) 2013-06-06
CN116942833A (zh) 2023-10-27
EP2785828A4 (en) 2015-07-29
US20180243348A1 (en) 2018-08-30
FI3978598T3 (fi) 2024-11-12
US10624933B2 (en) 2020-04-21
US11547732B2 (en) 2023-01-10
EP4477750A2 (en) 2024-12-18
JP6492151B2 (ja) 2019-03-27
US20210137998A1 (en) 2021-05-13
EP3978598B1 (en) 2024-08-28
WO2013080561A9 (en) 2013-08-08
EP4477750A3 (en) 2025-03-26
EP2785828A1 (en) 2014-10-08
US20160193256A1 (en) 2016-07-07
US10058578B2 (en) 2018-08-28
JP7165218B2 (ja) 2022-11-02
US20140341921A1 (en) 2014-11-20
US20170216378A1 (en) 2017-08-03
US10052353B2 (en) 2018-08-21
JP7503273B2 (ja) 2024-06-20
DK3569690T3 (da) 2024-11-11
JP2023015099A (ja) 2023-01-31
US9642881B2 (en) 2017-05-09
US10835559B2 (en) 2020-11-17
ES2993669T3 (en) 2025-01-03
HK1204008A1 (en) 2015-11-06
JP2015500792A (ja) 2015-01-08
US20170209502A1 (en) 2017-07-27
EP3978598A1 (en) 2022-04-06
CN104160014A (zh) 2014-11-19
JP2019134703A (ja) 2019-08-15
US10238694B2 (en) 2019-03-26
ES2994320T3 (en) 2025-01-22
US10183045B2 (en) 2019-01-22
US10342832B2 (en) 2019-07-09

Similar Documents

Publication Publication Date Title
JP7503273B2 (ja) 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
HK40119601A (en) Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
HK40070967B (en) Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
HK40070967A (en) Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
HK1261280B (en) Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20171214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180308

R150 Certificate of patent or registration of utility model

Ref document number: 6306507

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250